ArticleAnnals of nuclear medicine2025
A comparative study of dual-layer spectral CT and 18F-FDG-PET/CT multi-quantitative parameters in the diagnosis of sentinel lymph nodes in breast cancer.
Article in Annals of nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare the diagnostic efficacy of dual-layer spectral computed tomography (DSCT) and 18-F fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) in preoperative identification of metastatic sentinel lymph nodes (SLNs) in patients with breast cancer.
methodsThis retrospective study analyzed 97 patients who underwent DSCT and 107 patients who underwent 18F-FDG-PET/CT, classified by pathology into SLN-positive group and SLN-negative group. Quantitative measurements included: (1) DSCT parameters (normalized iodine concentration[nIC], effective atomic number [Zeff], the slope of the spectral Hounsfield unit curve [λHU] in both arterial and venous phases) and (2) the maximum standardized uptake value (SUVmax) of 18F-FDG PET/CT. Statistical analysis involved group comparisons, logistic regression for independent predictors, and receiver-operating characteristic (ROC) curve analysis (area under the curve [AUC], sensitivity, and specificity).
resultsThe results showed that SUVmax and spectral parameters, including Zeff in the venous phase, nIC in both arterial and venous phases, and λHU in both arterial and venous phases, were significantly higher in metastatic SLNs compared to non-metastatic SLNs. Logistic regression analysis identified both λHU in the venous phase and SUVmax as independent risk factors for predicting metastatic SLNs. ROC curve analysis indicated that SUVmax had a higher diagnostic efficiency (AUC: 0.905) than the combined spectral parameters (AUC: 0.834). Specifically, SUVmax demonstrated higher specificity (97 vs. 53%) but lower sensitivity (77 vs. 98%) than the spectral parameters.
conclusionsCompared with DSCT, 18F-FDG-PET/CT demonstrated higher specificity in identifying metastatic SLNs in breast cancer patients, but was less sensitive than spectral parameters. Spectral parameters can serve as a noninvasive tool for preoperative identification of metastatic SLNs in breast cancer.
Indexed as
Identifiers
40526186What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.